HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

The Consortium on Newborn Screening in Africa for sickle cell disease: study rationale and methodology.

Abstract
Sickle cell disease (SCD) is a common condition within sub-Saharan Africa and associated with high under-5 mortality (U5M). The American Society of Hematology instituted the Consortium on Newborn Screening in Africa (CONSA) for SCD, a 7-country network of sites to implement standardized newborn hemoglobinopathy screening and early intervention for children with SCD in sub-Saharan Africa. CONSA's overall hypothesis is that early infant SCD screening and entry into standardized, continuous care will reduce U5M compared with historical estimates in the region. Primary trial objectives are to determine the population-based birth incidence of SCD and effectiveness of early standardized care for preventing early mortality consortium-wide at each country's site(s). Secondary objectives are to establish universal screening and early interventions for SCD within clinical networks of CONSA partners and assess trial implementation. Outcomes will be evaluated from data collected using a shared patient registry. Standardized trial procedures will be implemented among designated birth populations in 7 African countries whose programs met eligibility criteria. Treatment protocol includes administering antibacterial and antimalarial prophylaxis and standard childhood vaccinations against infections commonly affecting children with SCD. Infants with a positive screen and confirmation of SCD within the catchment areas defined by each consortium partner will be enrolled in the clinical intervention protocol and followed regularly until age of 5 years. Effectiveness of these early interventions, along with culturally appropriate family education and counseling, will be evaluated by comparing U5M in the enrolled cohort to estimated preprogram data. Here, we describe the methodology planned for this trial.
AuthorsNancy S Green, Andrew Zapfel, Obiageli E Nnodu, Patience Franklin, Venée N Tubman, Lulu Chirande, Charles Kiyaga, Catherine Chunda-Liyoka, Bernard Awuonda, Kwaku Ohene-Frempong, Baba P D Inusa, Russell E Ware, Isaac Odame, Emmanuela E Ambrose, Livingstone G Dogara, Assaf P Oron, Chase Willett, Alexis A Thompson, Nancy Berliner, Theresa L Coetzer, Enrico M Novelli
JournalBlood advances (Blood Adv) Vol. 6 Issue 24 Pg. 6187-6197 (12 27 2022) ISSN: 2473-9537 [Electronic] United States
PMID36264096 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Copyright© 2022 by The American Society of Hematology. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved.
Topics
  • Infant
  • Child
  • Infant, Newborn
  • Humans
  • Child, Preschool
  • Neonatal Screening (methods)
  • Anemia, Sickle Cell (diagnosis, epidemiology, complications)
  • Africa South of the Sahara (epidemiology)
  • Incidence

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: